Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler » 10:03
05/21/20
05/21
10:03
05/21/20
10:03
GILD

Gilead

$73.09 /

-0.81 (-1.10%)

, GLPG

Galapagos

$204.87 /

-16.53 (-7.47%)

, PFE

Pfizer

$37.52 /

-0.11 (-0.29%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren reiterates an Overweight rating on Gilead Sciences (GILD) with a $90 price target following the "positive" topline data from the Phase II/III SELECTION trial with partner Galapagos (GLPG) evaluating filgotinib in ulcerative colitis patients. The data suggest filgotinib offers the potential for durable disease remission with both treatment-naive and treatment-experienced ulcerative colitis patients and that it could work in Crohn's too, Van Buren tells investors in a research note. The analyst believes the profile is competitive with Pfizer's (PFE) Xeljanz, which he notes is anticipated to generate $2.5B in sales this year and approach $3.5B by 2025. The 2025 consensus estimate for filgotinib is at $1.2B, which would be reasonable if we were just talking about the lead rheumatoid arthritis indication, says Van Buren. As such, he believes the Street is likely underestimating the peak sales potential of a "broadly utilized autoimmune drug" like filgotinib.

ShowHide Related Items >><<
PFE Pfizer
$37.52 /

-0.11 (-0.29%)

GLPG Galapagos
$204.87 /

-16.53 (-7.47%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

05/21/20 JPMorgan
Gilead Phase 3 ulcerative colitis study 'mixed at best,' says JPMorgan
05/13/20 Piper Sandler
KOL sees remdesivir as COVID-19 standard of care, says Piper Sandler
05/13/20 JPMorgan
Gilead already given 'ample market credit' for remdesivir, says JPMorgan
05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
GLPG Galapagos
$204.87 /

-16.53 (-7.47%)

05/21/20 H.C. Wainwright
Galapagos price target lowered to $270 from $302 at H.C. Wainwright
05/18/20 UBS
Galapagos price target raised to EUR 200 from EUR 194 at UBS
05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
PFE Pfizer
$37.52 /

-0.11 (-0.29%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
PFE Pfizer
$37.52 /

-0.11 (-0.29%)

GLPG Galapagos
$204.87 /

-16.53 (-7.47%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

PFE Pfizer
$37.52 /

-0.11 (-0.29%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

PFE Pfizer
$37.52 /

-0.11 (-0.29%)

GLPG Galapagos
$204.87 /

-16.53 (-7.47%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

PFE Pfizer
$37.52 /

-0.11 (-0.29%)

GILD Gilead
$73.09 /

-0.81 (-1.10%)

Recommendations
Galapagos price target lowered to $270 from $302 at H.C. Wainwright » 09:05
05/21/20
05/21
09:05
05/21/20
09:05
GLPG

Galapagos

$221.40 /

+1.91 (+0.87%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Debjit Chattopadhyay lowered the firm's price target on Galapagos to $270 from $302 and keeps a Buy rating on the shares. While the SELECTION trial met its primary endpoint in ulcerative colitis, the statistical significant benefit across all primary endpoints was limited to patients treated with the 200 mg dose, Chattopadhyay tells investors in a research note. The limited data in the press release and subsequent management commentary suggest a differentiated safety profile versus other JAKi's with no imbalance between the treatment and placebo cohorts, adds the analyst. He dropped his price target for Galapagos to reflect the "lack of clarity on a number of key metrics, potential overhang from the MANTA study, and importantly implications for the Crohn's Phase 3."

ShowHide Related Items >><<
GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

05/18/20 UBS
Galapagos price target raised to EUR 200 from EUR 194 at UBS
05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

Wednesday
On The Fly
Fly Intel: After-Hours Movers » 19:10
05/20/20
05/20
19:10
05/20/20
19:10
SCVL

Shoe Carnival

$24.34 /

+0.37 (+1.54%)

, HVT

Havertys

$15.28 /

+0.24 (+1.60%)

, EXPE

Expedia

$79.64 /

+3.26 (+4.27%)

, NDSN

Nordson

$175.31 /

+2.86 (+1.66%)

, ACB

Aurora Cannabis

$12.73 /

-1.86 (-12.75%)

, TTWO

Take-Two

$146.99 /

+4.73 (+3.32%)

, CPLG

CorePoint Lodging

$4.14 /

+0.39 (+10.40%)

, SKY

Skyline

$23.97 /

+1.615 (+7.22%)

, ZTO

ZTO Express

$34.30 /

-0.37 (-1.07%)

, YY

JOYY

$65.81 /

+2.52 (+3.98%)

, CPRT

Copart

$86.74 /

+2.79 (+3.32%)

, BOOT

Boot Barn

$22.28 /

+0.315 (+1.43%)

, HUYA

Huya

$19.25 /

+0.52 (+2.78%)

, GLPG

Galapagos

$221.40 /

+1.91 (+0.87%)

, SCPH

scPharmaceuticals

$10.90 /

+0.04 (+0.37%)

, FLXN

Flexion

$10.92 /

+0.39 (+3.70%)

, RUTH

Ruth's Hospitality

$9.11 /

+0.16 (+1.79%)

, BSX

Boston Scientific

$37.19 /

+1.78 (+5.03%)

, KDP

Keurig Dr Pepper

$27.69 /

+0.48 (+1.76%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YY JOYY
$65.81 /

+2.52 (+3.98%)

TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

SKY Skyline
$23.97 /

+1.615 (+7.22%)

SCVL Shoe Carnival
$24.34 /

+0.37 (+1.54%)

SCPH scPharmaceuticals
$10.90 /

+0.04 (+0.37%)

RUTH Ruth's Hospitality
$9.11 /

+0.16 (+1.79%)

NDSN Nordson
$175.31 /

+2.86 (+1.66%)

KDP Keurig Dr Pepper
$27.69 /

+0.48 (+1.76%)

HVT Havertys
$15.28 /

+0.24 (+1.60%)

HUYA Huya
$19.25 /

+0.52 (+2.78%)

GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

FLXN Flexion
$10.92 /

+0.39 (+3.70%)

EXPE Expedia
$79.64 /

+3.26 (+4.27%)

CPRT Copart
$86.74 /

+2.79 (+3.32%)

CPLG CorePoint Lodging
$4.14 /

+0.39 (+10.40%)

BSX Boston Scientific
$37.19 /

+1.78 (+5.03%)

BOOT Boot Barn
$22.28 /

+0.315 (+1.43%)

ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

SCVL Shoe Carnival
$24.34 /

+0.37 (+1.54%)

03/26/20 Wedbush
Shoe Carnival price target lowered to $25 from $44 at Wedbush
03/19/20 Susquehanna
Shoe Carnival price target lowered to $18 from $47 at Susquehanna
11/13/19 Wedbush
Shoe Carnival price target raised to $42 from $32 at Wedbush
10/09/19 Susquehanna
Shoe Carnival benefiting from competitors struggles, says Susquehanna
HVT Havertys
$15.28 /

+0.24 (+1.60%)

08/13/19
Haverty Furniture management to meet with Sidoti
EXPE Expedia
$79.64 /

+3.26 (+4.27%)

05/19/20
Fly Intel: Top five analyst downgrades
05/19/20 Jefferies
Jefferies downgrades Expedia to Hold on 'long road to recovery'
05/19/20 Jefferies
Expedia downgraded to Hold from Buy at Jefferies
05/06/20 Deutsche Bank
Deutsche downgrades TripAdvisor on lack of confidence in travel rebound
NDSN Nordson
$175.31 /

+2.86 (+1.66%)

04/17/20 Jefferies
Nordson initiated with a Buy at Jefferies
04/06/20 KeyBanc
KeyBanc upgrades 'best-in-class asset' Nordson to Overweight
04/06/20 KeyBanc
Nordson upgraded to Overweight from Sector Weight at KeyBanc
03/16/20 Wells Fargo
Wells Fargo upgrades Nordson on 'increasingly favorable' risk/reward
ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

05/19/20 CIBC
Aurora Cannabis price target lowered to C$14 from C$27 at CIBC
05/19/20 MKM Partners
Aurora Cannabis price target raised to C$18 from C$12 at MKM Partners
05/15/20 MKM Partners
Aurora Cannabis price target raised to C$12 from C$1 at MKM Partners
05/15/20 Piper Sandler
Aurora Cannabis upgraded to Neutral from Underweight at Piper Sandler
TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

05/19/20 Benchmark
Take-Two price target raised to $149 from $142 at Benchmark
05/15/20 Piper Sandler
Piper survey finds people are playing more video games during COVID-19
05/12/20 Stephens
Electronic Arts named a Best Idea at Stephens
04/06/20 Wells Fargo
Take-Two initiated with an Overweight at Wells Fargo
CPLG CorePoint Lodging
$4.14 /

+0.39 (+10.40%)

01/17/20 Deutsche Bank
CorePoint Lodging initiated with a Buy at Deutsche Bank
12/20/19 Stifel
DiamondRock named top lodging REIT pick for 2020 at Stifel
08/16/19 Stifel
Wyndham Hotels selloff on CorePoint comments seems overdone, says Stifel
07/09/19
Fly Intel: Top five analyst downgrades
SKY Skyline
$23.97 /

+1.615 (+7.22%)

05/20/20 SunTrust
SunTrust upgrades Skyline to Buy ahead of today's earnings report
05/20/20 SunTrust
Skyline upgraded to Buy from Hold at SunTrust
04/07/20 RBC Capital
Skyline downgraded to Sector Perform from Outperform at RBC Capital
04/07/20 RBC Capital
Skyline downgraded to Sector Perform from Outperform at RBC Capital
ZTO ZTO Express
$34.30 /

-0.37 (-1.07%)

03/19/20
ZTO Express downgraded to Hold from Buy at CMB International
YY JOYY
$65.81 /

+2.52 (+3.98%)

05/20/20 Morgan Stanley
Morgan Stanley upgrades JOYY to Overweight on stepping up monetization of Likee
05/20/20 Morgan Stanley
JOYY upgraded to Overweight from Equal Weight at Morgan Stanley
11/13/19 Nomura Instinet
YY price target raised to $77 from $70 at Nomura Instinet
09/20/19 UBS
YY upgraded to Buy from Neutral at UBS
CPRT Copart
$86.74 /

+2.79 (+3.32%)

05/18/20 SunTrust
Copart price target lowered to $90 from $110 at SunTrust
04/23/20 JPMorgan
Copart upgraded to Neutral on end-market resiliency at JPMorgan
04/23/20 JPMorgan
Copart upgraded to Neutral from Underweight at JPMorgan
04/09/20 Jefferies
Jefferies sees road congestion returning in 2021, upgrades Copart to Buy
BOOT Boot Barn
$22.28 /

+0.315 (+1.43%)

04/15/20 Susquehanna
Boot Barn downgraded to Negative at Susquehanna
04/15/20 Susquehanna
Boot Barn downgraded to Negative from Neutral at Susquehanna
03/30/20 Craig-Hallum
Boot Barn price target lowered to $18 from $53 at Craig-Hallum
03/13/20 Cowen
Boot Barn price target lowered to $25 from $50 at Cowen
HUYA Huya
$19.25 /

+0.52 (+2.78%)

03/26/20 Goldman Sachs
Huya upgraded to Buy from Neutral at Goldman Sachs
03/20/20 China Renaissance
Huya upgraded to Buy on valuation at China Renaissance
03/20/20 China Renaissance
Huya upgraded to Buy from Hold at China Renaissance
02/26/20
Fly Intel: Top five analyst downgrades
GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

05/18/20 UBS
Galapagos price target raised to EUR 200 from EUR 194 at UBS
05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
SCPH scPharmaceuticals
$10.90 /

+0.04 (+0.37%)

05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
10/15/19 H.C. Wainwright
scPharmaceuticals initiated with a Buy at H.C. Wainwright
FLXN Flexion
$10.92 /

+0.39 (+3.70%)

05/08/20 Needham
Flexion price target lowered to $20 from $30 at Needham
04/02/20 Benchmark
Flexion price target lowered to $17 from $25 at Benchmark
01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
12/27/19 Wells Fargo
Flexion remains a best idea at Wells Fargo after label approval
RUTH Ruth's Hospitality
$9.11 /

+0.16 (+1.79%)

03/17/20
Fly Intel: Top five analyst downgrades
03/17/20 Piper Sandler
Ruth's Hospitality downgraded to Neutral from Overweight at Piper Sandler
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 CL King
Ruth's Hospitality initiated with a Neutral at CL King
BSX Boston Scientific
$37.19 /

+1.78 (+5.03%)

05/10/20 Piper Sandler
FLX to further strengthen Boston category leadership in LAAC, says Piper Sandler
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform at SVB Leerink on slower recovery
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform from Outperform at SVB Leerink
KDP Keurig Dr Pepper
$27.69 /

+0.48 (+1.76%)

04/01/20 Goldman Sachs
Keurig Dr Pepper resumed with a Neutral at Goldman Sachs
03/05/20 BofA
Mondelez could sell Keurig Dr Pepper shares to fund M&A, says BofA
02/24/20
Fly Intel: Top five analyst upgrades
02/24/20 Morgan Stanley
Morgan Stanley upgrades Keurig Dr Pepper to Equal Weight after underperformance
ZTO ZTO Express
$34.30 /

-0.37 (-1.07%)

YY JOYY
$65.81 /

+2.52 (+3.98%)

TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

SKY Skyline
$23.97 /

+1.615 (+7.22%)

SCVL Shoe Carnival
$24.34 /

+0.37 (+1.54%)

SCPH scPharmaceuticals
$10.90 /

+0.04 (+0.37%)

RUTH Ruth's Hospitality
$9.11 /

+0.16 (+1.79%)

NDSN Nordson
$175.31 /

+2.86 (+1.66%)

KDP Keurig Dr Pepper
$27.69 /

+0.48 (+1.76%)

HVT Havertys
$15.28 /

+0.24 (+1.60%)

HUYA Huya
$19.25 /

+0.52 (+2.78%)

GLPG Galapagos
$221.40 /

+1.91 (+0.87%)

FLXN Flexion
$10.92 /

+0.39 (+3.70%)

EXPE Expedia
$79.64 /

+3.26 (+4.27%)

CPRT Copart
$86.74 /

+2.79 (+3.32%)

CPLG CorePoint Lodging
$4.14 /

+0.39 (+10.40%)

BSX Boston Scientific
$37.19 /

+1.78 (+5.03%)

BOOT Boot Barn
$22.28 /

+0.315 (+1.43%)

ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

  • 21
    May
  • 22
    May
  • 21
    May
  • 21
    May
  • 21
    May
TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

KDP Keurig Dr Pepper
$27.69 /

+0.48 (+1.76%)

EXPE Expedia
$79.64 /

+3.26 (+4.27%)

CPRT Copart
$86.74 /

+2.79 (+3.32%)

BSX Boston Scientific
$37.19 /

+1.78 (+5.03%)

ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

SCVL Shoe Carnival
$24.34 /

+0.37 (+1.54%)

RUTH Ruth's Hospitality
$9.11 /

+0.16 (+1.79%)

NDSN Nordson
$175.31 /

+2.86 (+1.66%)

KDP Keurig Dr Pepper
$27.69 /

+0.48 (+1.76%)

FLXN Flexion
$10.92 /

+0.39 (+3.70%)

EXPE Expedia
$79.64 /

+3.26 (+4.27%)

CPRT Copart
$86.74 /

+2.79 (+3.32%)

BOOT Boot Barn
$22.28 /

+0.315 (+1.43%)

ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

TTWO Take-Two
$146.99 /

+4.73 (+3.32%)

SCVL Shoe Carnival
$24.34 /

+0.37 (+1.54%)

NDSN Nordson
$175.31 /

+2.86 (+1.66%)

HUYA Huya
$19.25 /

+0.52 (+2.78%)

EXPE Expedia
$79.64 /

+3.26 (+4.27%)

CPRT Copart
$86.74 /

+2.79 (+3.32%)

BSX Boston Scientific
$37.19 /

+1.78 (+5.03%)

ACB Aurora Cannabis
$12.73 /

-1.86 (-12.75%)

Hot Stocks
Galapagos, Gilead report Phase 2B/3 results from filgotinib study » 16:09
05/20/20
05/20
16:09
05/20/20
16:09
GLPG

Galapagos

$220.71 /

+1.22 (+0.56%)

, GILD

Gilead

$73.66 /

+1.35 (+1.87%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Galapagos (GLPG) announced "positive topline results from Selection a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in or biologic-experienced adult patients with moderately to severely active ulcerative colitis UC. Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo. Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10. "We are encouraged by the early response as an induction therapy and the durable efficacy as a maintenance therapy observed in the SELECTION trial," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "Patients with moderate to severe ulcerative colitis can struggle to effectively manage their disease. These topline data suggest that filgotinib could play a role in helping more patients achieve a meaningful and sustained improvement in treatment response with an oral therapy."

ShowHide Related Items >><<
GLPG Galapagos
$220.71 /

+1.22 (+0.56%)

GILD Gilead
$73.66 /

+1.35 (+1.87%)

GLPG Galapagos
$220.71 /

+1.22 (+0.56%)

05/18/20 UBS
Galapagos price target raised to EUR 200 from EUR 194 at UBS
05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
GILD Gilead
$73.66 /

+1.35 (+1.87%)

05/13/20 Piper Sandler
KOL sees remdesivir as COVID-19 standard of care, says Piper Sandler
05/13/20 JPMorgan
Gilead already given 'ample market credit' for remdesivir, says JPMorgan
05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
GLPG Galapagos
$220.71 /

+1.22 (+0.56%)

GILD Gilead
$73.66 /

+1.35 (+1.87%)

GILD Gilead
$73.66 /

+1.35 (+1.87%)

GILD Gilead
$73.66 /

+1.35 (+1.87%)

GILD Gilead
$73.66 /

+1.35 (+1.87%)

Over a week ago
Recommendations
Galapagos price target raised to EUR 200 from EUR 194 at UBS » 14:56
05/18/20
05/18
14:56
05/18/20
14:56
GLPG

Galapagos

$221.40 /

+4.35 (+2.00%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe raised the firm's price target on Galapagos to EUR 200 from EUR 194 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
GLPG Galapagos
$221.40 /

+4.35 (+2.00%)

GLPG Galapagos
$221.40 /

+4.35 (+2.00%)

05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
GLPG Galapagos
$221.40 /

+4.35 (+2.00%)

Recommendations
Galapagos price target raised to EUR 235 from EUR 225 at Barclays » 12:56
05/15/20
05/15
12:56
05/15/20
12:56
GLPG

Galapagos

$217.05 /

+6.16 (+2.92%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Galapagos to EUR 235 from EUR 225 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GLPG Galapagos
$217.05 /

+6.16 (+2.92%)

GLPG Galapagos
$217.05 /

+6.16 (+2.92%)

05/08/20
Galapagos downgraded to Hold from Buy at Degroof Petercam
03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
GLPG Galapagos
$217.05 /

+6.16 (+2.92%)

Downgrade
Galapagos downgraded to Hold from Buy at Degroof Petercam » 05:28
05/08/20
05/08
05:28
05/08/20
05:28
GLPG

Galapagos

$224.83 /

+4.32 (+1.96%)

Degroof Petercam analyst…

Degroof Petercam analyst Benoit Louage downgraded Galapagos to Hold from Buy with a EUR 220 price target.

ShowHide Related Items >><<
GLPG Galapagos
$224.83 /

+4.32 (+1.96%)

03/30/20 Jefferies
Galapagos upgraded to Buy from Hold at Jefferies
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
02/26/20 Nomura Instinet
Galapagos price target raised to $290 from $209 at Nomura Instinet
Over a month ago
Upgrade
Galapagos upgraded to Buy from Hold at Jefferies » 09:16
03/30/20
03/30
09:16
03/30/20
09:16
GLPG

Galapagos

$182.09 /

-4.71 (-2.52%)

Jefferies analyst Peter…

Jefferies analyst Peter Welford upgraded Galapagos to Buy from Hold with a price target of $232, down from $243. He is optimistic that the upcoming filgotinib Phase 3 SELECTION ulcerative colitis data will be positive and suspects filgotinib will be at least be on par with Xeljanz' efficacy, but with a potentially best-in-class safety profile, the analyst tells investors. He forecasts $6B in worldwide peak sales for filgotinib, Welford noted.

ShowHide Related Items >><<
GLPG Galapagos
$182.09 /

-4.71 (-2.52%)

03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
02/26/20 Nomura Instinet
Galapagos price target raised to $290 from $209 at Nomura Instinet
02/25/20 Cantor Fitzgerald
Galapagos downgraded to Neutral on valuation at Cantor Fitzgerald
Upgrade
Galapagos upgraded to Sector Perform from Underperform at RBC Capital » 06:28
03/18/20
03/18
06:28
03/18/20
06:28
GLPG

Galapagos

$156.75 /

-4.26 (-2.65%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams upgraded Galapagos to Sector Perform from Underperform with a price target of $157, down from $175. The analyst notes that after the recent 43% downside from February highs, the stock more fairly reflects the value of Filgotinib and the company's pipeline within the autoimmune-focused R&D platform as balanced against risks. Abrahams adds that Galapagos' pipeline and strong balance sheet should offer the company greater optionality and staying power.

ShowHide Related Items >><<
GLPG Galapagos
$156.75 /

-4.26 (-2.65%)

03/18/20 RBC Capital
Galapagos upgraded to Sector Perform from Underperform at RBC Capital
02/26/20 Nomura Instinet
Galapagos price target raised to $290 from $209 at Nomura Instinet
02/25/20 Cantor Fitzgerald
Galapagos downgraded to Neutral on valuation at Cantor Fitzgerald
02/25/20 Cantor Fitzgerald
Galapagos downgraded to Neutral from Overweight at Cantor Fitzgerald
Upgrade
Galapagos upgraded to Sector Perform from Underperform at RBC Capital » 06:15
03/18/20
03/18
06:15
03/18/20
06:15
GLPG

Galapagos

$156.75 /

-4.26 (-2.65%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams upgraded Galapagos to Sector Perform from Underperform with a price target of $157, down from $175.

ShowHide Related Items >><<
GLPG Galapagos
$156.75 /

-4.26 (-2.65%)

02/26/20 Nomura Instinet
Galapagos price target raised to $290 from $209 at Nomura Instinet
02/25/20 Cantor Fitzgerald
Galapagos downgraded to Neutral on valuation at Cantor Fitzgerald
02/25/20 Cantor Fitzgerald
Galapagos downgraded to Neutral from Overweight at Cantor Fitzgerald
02/24/20 H.C. Wainwright
Galapagos price target raised to $302 from $205 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.